DOCSLIB.ORG

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects Clin Pharmacokinet DOI 10.1007/s40262-017-0513-9 ORIGINAL RESEARCH ARTICLE Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects 1,3 1 2 2 Patrick C. Dolder • Yasmin Schmid • Andrea E. Steuer • Thomas Kraemer • 3 1 1 Katharina M. Rentsch • Felix Hammann • Matthias E. Liechti Ó The Author(s) 2017. This article is published with open access at Springerlink.com Abstract repeatedly assessed. Pharmacokinetic parameters were Background and Objective Lysergic acid diethylamide determined using compartmental modeling. Concentration- (LSD) is used recreationally and in clinical research. The effect relationships were described using pharmacokinetic- aim of the present study was to characterize the pharma- pharmacodynamic modeling. cokinetics and exposure–response relationship of oral LSD. Results Geometric mean (95% confidence interval) maxi- Methods We analyzed pharmacokinetic data from two mum plasma concentration values of 1.3 (1.2–1.9) and 3.1 published placebo-controlled, double-blind, cross-over (2.6–4.0) ng/mL were reached 1.4 and 1.5 h after admin- studies using oral administration of LSD 100 and 200 lgin istration of 100 and 200 lg LSD, respectively. The plasma 24 and 16 subjects, respectively. The pharmacokinetics of half-life was 2.6 h (2.2–3.4 h). The subjective effects las- the 100-lg dose is shown for the first time and data for the ted (mean ± standard deviation) 8.2 ± 2.1 and 200-lg dose were reanalyzed and included. Plasma con- 11.6 ± 1.7 h for the 100- and 200-lg LSD doses, respec- centrations of LSD, subjective effects, and vital signs were tively. Subjective peak effects were reached 2.8 and 2.5 h after administration of LSD 100 and 200 lg, respectively. A close relationship was observed between the LSD con- centration and subjective response within subjects, with moderate counterclockwise hysteresis. Half-maximal effective concentration values were in the range of 1 ng/ mL. No correlations were found between plasma LSD concentrations and the effects of LSD across subjects at or near maximum plasma concentration and within dose groups. Electronic supplementary material The online version of this Conclusions The present pharmacokinetic data are article (doi:10.1007/s40262-017-0513-9) contains supplementary important for the evaluation of clinical study findings (e.g., material, which is available to authorized users. functional magnetic resonance imaging studies) and the interpretation of LSD intoxication. Oral LSD presented & Matthias E. Liechti [email protected] dose-proportional pharmacokinetics and first-order elimi- nation up to 12 h. The effects of LSD were related to 1 Division of Clinical Pharmacology and Toxicology, changes in plasma concentrations over time, with no evi- Department of Biomedicine and Department of Clinical dence of acute tolerance. Research, University Hospital Basel, Hebelstrasse 2, 4031 Basel, Switzerland Trial registration: NCT02308969, NCT01878942. 2 Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland 3 Laboratory Medicine, University Hospital Basel, Basel, Switzerland P. C. Dolder et al. second goal was to link the plasma concentration changes Key Points over time within subjects to the acute subjective and autonomic effects of LSD to derive half-maximal effective The pharmacokinetics of lysergic acid diethylamide concentration (EC50) values using standard pharmacoki- was dose proportional and the subjective effects netic-pharmacodynamic modeling. were related to the time course of plasma Researchers have correlated subjective drug effects with concentrations within subjects, with no evidence of brain functional magnetic resonance imaging (fMRI) data acute tolerance. [12, 13, 16, 17]. This approach likely detects significant correlations for subjective effects that show large between- Between-subject differences in plasma subject variance but not for subjective effects of the sub- concentrations of lysergic acid diethylamide did not stance that are consistently present in all subjects. Plasma predict the subjective response within a dose group concentrations of LSD have not been determined in any of and when plasma concentrations were above the the published LSD fMRI studies to date; therefore, it is half-maximal effective concentration of the response unclear how LSD exposure in the body is linked to sub- measures. jective effects in these studies. Therefore, a further goal of the present study was to assess associations across subjects between plasma exposure to LSD and the pharmacody- namic effects at corresponding times. 1 Introduction The present study combined data from two similar clinical studies that tested 100- and 200-lg doses of LSD in Lysergic acid diethylamide (LSD) is the prototypical hal- 24 and 16 healthy subjects, respectively. The pharma- lucinogen [1, 2]. Lysergic acid diethylamide has seen cokinetic data and concentration–effect relationship of worldwide interest with regard to pharmacology, psychia- 100 lg LSD are presented. Similar data on 200 lg LSD try, and society at large. Lysergic acid diethylamide con- have been previously reported [23]. In the present study, tinues to be used for recreational and personal purposes [3]. plasma concentrations after 200 lg LSD administration Additionally, considerable interest has been seen in its were newly measured using a more sensitive and specific therapeutic potential [4–9], and experimental clinical analytical method. The results were included for compar- research with LSD has recently been reinitiated [10–23]. isons with the 100-lg data and to newly evaluate However, basic pharmacokinetic information on LSD is dose/concentration–response effects. The subjective effects largely missing. A small study in five male subjects of LSD have been reported for both doses, but relationships reported a mean plasma elimination half-life of LSD of to plasma exposure were not evaluated [21]. 175 min after intravenous administration (2 lg/kg) [24]. Another non-systematic study sampled blood after admin- istration of LSD 160 lg in 13 subjects up to 2.5–5 h but 2 Methods because of sparse and short sampling could not derive pharmacokinetic parameters [25]. We recently reported the 2.1 Study Design first pharmacokinetic data for orally administered LSD (200 lg) in 16 male and female subjects [23]. The con- We performed the pharmacokinetic data analysis on two centrations of LSD were maximal after 1.5 h (median) and similar previously performed studies [21–23] using double- gradually declined to very low levels by 12 h, with an blind, placebo-controlled, cross-over designs with two elimination half-life of 3.6 h [23]. experimental test sessions (LSD and placebo) in a balanced Recent studies have reported the effects of LSD on order. Study 1 used a dose of LSD 100 lg and placebo in various neuronal correlates of brain activation 24 subjects. Study 2 used LSD 200 lg and placebo in 16 [12, 13, 16, 17]. However, plasma exposure and thus the subjects. The washout periods between sessions were at actual presence of LSD in the body have not been docu- least 7 days. The studies were registered at ClinicalTri- mented in any of these studies to date. Unknown are the als.gov (NCT02308969, NCT01878942). time point at which peak concentrations are reached and the actual or predicted concentrations of LSD at the time 2.2 Participants point at which pharmacodynamic outcomes were collected. Therefore, the primary goal of the present study was to Forty healthy participants were recruited from the describe the pharmacokinetics of a controlled administra- University of Basel campus via an online advertisement. tion of oral LSD by assessing the plasma concentration- Twenty-four subjects [12 men, 12 women; age time profile of two doses of LSD (100 and 200 lg). A 33 ± 11 years (mean ± standard deviation); range Pharmacokinetics-Pharmacodynamics of LSD 25–60 years; body weight: 68 ± 8 kg, 55–85 kg) partici- 2.4 Study Drug pated in Study 1 (100 lg), and 16 subjects (eight men, eight women; age 29 ± 6 years; range 25–51 years; body Lysergic acid diethylamide (d-lysergic acid diethylamide weight: 72 ± 12 kg, 52–98 kg) participated in Study 2 hydrate, high-performance liquid chromatography pur- (200 lg). The inclusion and exclusion criteria were iden- ity [99%; Lipomed AG, Arlesheim, Switzerland) was tical for both studies. The exclusion criteria were administered in a single oral dose of 100 or 200 lgasa age \25 years or [65 years, pregnancy (urine pregnancy capsule (Bichsel Laboratories, Interlaken, Switzerland). test at screening and before each test session), personal or Both doses were within the range of doses that are taken for family (first-degree relative) history of major psychiatric recreational purposes [1]. The 200-lg dose (the same disorders (assessed by the semi-structured clinical inter- capsules) was also used in LSD-assisted psychotherapy in view for Diagnostic and Statistical Manual of Mental patients [6], and intravenous doses of 75–100 lg have been Disorders, 4th edition, Axis I disorders by the study used in fMRI studies in healthy subjects [13]. physician and an additional interview by a trained psy- chiatrist), use of medications that may interfere with the 2.5 Measures study drug, chronic or acute physical illness (abnormal physical examination, electrocardiogram, or hematological 2.5.1 Blood Sampling and chemical blood analyses), tobacco smoking (more than ten cigarettes/day), lifetime prevalence of illicit drug use Blood was collected into lithium heparin tubes before and more than ten times (except for tetrahydrocannabinol), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 h after LSD illicit drug use within the previous 2 months, and illicit drug administration. The 0.5-, 1.5-, and 2.5-h samples were not use during the study. We performed urine drug tests at collected in Study 1 (100 lg). The blood samples were screening and before each test session, and no substances immediately centrifuged, and the plasma was rapidly stored were detected during the study.
Load more

Recommended publications
  • 2020 Prior Authorization Criteria
    2020 PRIOR AUTHORIZATION CRITERIA TABLE OF CONTENTS abiraterone tablet ...................................................................................................................... 217 ABRAXANE .............................................................................................................................. 131 ACTIMMUNE .............................................................................................................................. 14 ADASUVE ................................................................................................................................... 27 ADEMPAS ................................................................................................................................ 197 AFINITOR ................................................................................................................................. 217 AFINITOR DISPERZ ................................................................................................................. 217 AIMOVIG ..................................................................................................................................... 15 ALECENSA ............................................................................................................................... 217 ALIMTA ..................................................................................................................................... 131 ALIQOPA .................................................................................................................................
    [Show full text]
  • Switching from Clonidine Immediate-Release to Guanfacine Extended-Release
    / DE L’ACADÉMIE CANADIENNE DE PSYCHIATRIE DE L’ENFANT ET DE L’ADOLESCENT PSYCHOPHARMACOLOGY Switching from Clonidine Immediate-Release to Guanfacine Extended-Release Dean Elbe PharmD, BCPP1,2,3 s a clinical pharmacy specialist in child and adolescent (Canada) Ltd, 2012b). Clonidine has been used off-label Amental health, I am frequently asked how to switch in children for many years for treatment of insomnia, patients from clonidine immediate-release (IR) to guanfa- ADHD, and disruptive behaviour disorders (Hunt, Capper cine extended-release (XR). This therapeutic switch may be & O’Connell, 1990; Rubinstein; Jaselskis, Cook, Fletcher required when poor adherence to a clonidine IR regimen & Leventhal, 1992; Silver & Licamele, 1994; Palumbo et (typically requiring 3–4 doses daily) is identified, when al., 2008; Efron, Lycett & Sciberras, 2014). A clonidine XR clonidine dose-optimization is limited by sedation, brady- formulation is not available in Canada, but is available in cardia or hypotension, or when coverage situations change. the United States for treatment of ADHD (Concordia Phar- The latter may occur if, for example, new eligibility for a maceuticals, Inc. 2015). government program or a third party-payer occurs. Weight-based dosing guidelines exist for clonidine IR Guanfacine XR, a selective alpha2A agonist, was first mar- (0.003–0.008 mg/kg/day) and guanfacine XR (0.05–0.08 keted in Canada in late 2013 for the treatment of attention mg/kg/day) (Shire Pharma Canada ULC, 2019; Elbe et deficit hyperactivity disorder (ADHD) in children and ado- al., 2018). Based on these guidelines and other literature, lescents (Shire Pharma Canada ULC, 2019).
    [Show full text]
  • M2021: Pharmacogenetic Testing
    Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs).
    [Show full text]
  • Memory Deficits Associated with Clonidine
    Letter to the Editor Letters to the Editor are invited for comment on a topic of current interest or on Table material published in GENERAL HOSPITAL PSYCHIATRY. Letters should be typed doubled spaced and are subject to editing according to space limitations. - Memory Deficits Associated with Attent KnO Clonidine WA Verbal WA Drugs used in the treatment of essential hyperten- Initiation of clonidine therapy (0.1 mg b.i.d.) in WA sion are among the most commonly prescribed. April 1984 resulted in well-controlled hypertension Tactilc Some of these agents have primary effects on neu- without immediately apparent adverse effects. Fulc rotransmitter systems and are centrally active. However, the coincidence of the onset of memory Verba Thus, drugs such as a-methyldopa, propranalol, complaints and the beginning of clonidine treat- 3% ment suggested that clonidine might be respon- List Ll and reserpine have well-established neuropsychia- Fulc tric complications, ranging from depression to cog- sible. si nitive impairments and psychosis [l].Since the use After consultation with the patient's internist, a R of these drugs is widespread and unavoidable, we switch was made to captopril, an angiotensin-con- T must be alert to the possibility that these drugs verting enzyme inhibitor. Before the change we T administered tests of attention, concentration, and contribute to psychologic complaints and symp- -R toms of our patients. verbal skills as well as the Fuld Object-Memory Evaluation, which includes a measure of verbal 'Age-a Clonidine, a presynaptic adrenergic a2agonist, bNonc has become well established as a useful and rela- fluency as well as a selective reminding list learning tively safe therapeutic agent.
    [Show full text]
  • Different Beta-Blocking Effects of Carvedilol and Bisoprolol in Humans
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2001; 4 (1), 53-56 Different beta-blocking effects of carvedilol and bisoprolol in humans Koshucharova G, Klein W, Lercher P, Maier R, Stepan V Stoschitzky K, Zweiker R Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL CARDIOLOGY Different Beta-Blocking Effects of Carvedilol and Bisoprolol J Clin Basic Cardiol 2001; 4: 53 Different Beta-Blocking Effects of Carvedilol and Bisoprolol in Humans G. Koshucharova, R. Zweiker, R. Maier, P. Lercher, V. Stepan, W. Klein, K. Stoschitzky Bisoprolol is a beta1-selective beta-adrenergic antagonist while carvedilol is a non-selective beta-blocker with additional blockade of alpha1-adrenoceptors. Administration of bisoprolol has been shown to cause up-regulation of β-adrenoceptor density and to decrease nocturnal melatonin release, whereas carvedilol lacks these typical effects of beta-blocking drugs. The objective of the present study was to investigate beta-blocking effects of bisoprolol and carvedilol in healthy subjects. We compared the effects of single oral doses of clinically recommended amounts of bisoprolol (2.5, 5 and 10 mg) and carvedilol (25, 50 and 100 mg) to those of placebo in a randomised, double-blind, cross-over study in 12 healthy male volun- teers. Three hours after oral administration of the drugs heart rate and blood pressure were measured at rest, after 10 min. of exercise, and after 15 min.
    [Show full text]
  • Tall Man Lettering List REPORT DECEMBER 2013 1
    Tall Man Lettering List REPORT DECEMBER 2013 1 TALL MAN LETTERING LIST REPORT WWW.HQSC.GOVT.NZ Published in December 2013 by the Health Quality & Safety Commission. This document is available on the Health Quality & Safety Commission website, www.hqsc.govt.nz ISBN: 978-0-478-38555-7 (online) Citation: Health Quality & Safety Commission. 2013. Tall Man Lettering List Report. Wellington: Health Quality & Safety Commission. Crown copyright ©. This copyright work is licensed under the Creative Commons Attribution-No Derivative Works 3.0 New Zealand licence. In essence, you are free to copy and distribute the work (including other media and formats), as long as you attribute the work to the Health Quality & Safety Commission. The work must not be adapted and other licence terms must be abided. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nd/3.0/nz/ Copyright enquiries If you are in doubt as to whether a proposed use is covered by this licence, please contact: National Medication Safety Programme Team Health Quality & Safety Commission PO Box 25496 Wellington 6146 ACKNOWLEDGEMENTS The Health Quality & Safety Commission acknowledges the following for their assistance in producing the New Zealand Tall Man lettering list: • The Australian Commission on Safety and Quality in Health Care for advice and support in allowing its original work to be either reproduced in whole or altered in part for New Zealand as per its copyright1 • The Medication Safety and Quality Program of Clinical Excellence Commission, New South
    [Show full text]
  • Sleep & Dreams & Dsm-5
    PAL Conference - Green River, WY - May 2015 SLEEP & DREAMS & DSM-5: ASSESSMENT AND TREATMENT OF PEDIATRIC INSOMNIA James Peacey, MD PAL Conference Green River, WY Disclosure Statement No relevant financial relationships with the manufacturer(s) of any commercial product(s) and/or provider of commercial services discussed in this CME activity. I will reference off-label or investigational use of medications in this presentation. PAL Conference - Green River, WY - May 2015 Goals and Objectives Learn how to identify and categorize pediatric insomnia. Increase knowledge of common behavioral and pharmacologic sleep treatments. Increase understanding of sleep issues in particular patient populations (Autism, ADHD, depression and anxiety) and appropriate strategies to optimize treatment. PAL Conference - Green River, WY - May 2015 Sleep Stage Development PAL Conference - Green River, WY - May 2015 Homeostatic and Circadian Processes D. J. Dijk and D. M. Edgar, Regulation of Sleep and Wakefulness, 1999 PAL Conference - Green River, WY - May 2015 Homeostatic and Circadian Processes PAL Conference - Green River, WY - May 2015 Alerting Systems PAL Conference - Green River, WY - May 2015 Normal Sleep Requirements Babcock, Pediatr Clin N Am 58 (2011) 543–554PAL Conference - Green River, WY - May 2015 Percentiles for total sleep duration per 24 hours from infancy to adolescence. Iglowstein I et al. Pediatrics 2003;111:302-307 PAL Conference - Green River, WY - May 2015 ©2003 by American Academy of Pediatrics Insomnia “significant difficulty initiating
    [Show full text]
  • IHS National Pharmacy & Therapeutics Committee National
    IHS National Pharmacy & Therapeutics Committee National Core Formulary; Last Updated: 09/23/2021 **Note: Medications in GREY indicate removed items.** Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief (if Notes / Similar NCF Active? available) Miscellaneous Medications Acetaminophen Analgesic, Miscellaneous Yes Albuterol nebulized solution Beta2 Agonist Yes Albuterol, metered dose inhaler Beta2 Agonist NPTC Meeting Update *Any product* Yes (MDI) (Nov 2017) Alendronate Bisphosphonate Derivative Osteoporosis (2016) Yes Allopurinol Antigout Agent; Xanthine Oxidase Inhibitor Gout (2016) Yes Alogliptin Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor DPP-IV Inhibitors (2019) Yes Anastrozole Antineoplastic Agent, Aromatase Inhibitor Yes Aspirin Antiplatelet Agent; Nonsteroidal Anti-Inflammatory Drug; Salicylate Yes Azithromycin Antibiotic, Macrolide STIs - PART 1 (2021) Yes Calcium Electrolyte supplement *Any formulation* Yes Carbidopa-Levodopa (immediate Anti-Parkinson Agent; Decarboxylase Inhibitor-Dopamine Precursor Parkinson's Disease Yes release) (2019) Clindamycin, topical ===REMOVED from NCF=== (See Benzoyl Peroxide AND Removed January No Clindamycin, topical combination) 2020 Corticosteroid, intranasal Intranasal Corticosteroid *Any product* Yes Cyanocobalamin (Vitamin B12), Vitamin, Water Soluble Hematologic Supplements Yes oral (2016) Printed on 09/25/2021 Page 1 of 18 National Core Formulary; Last Updated: 09/23/2021 Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief
    [Show full text]
  • Carvedilol an 3.125, 6.25, 12.5 & 25 Mg Tablets
    Carvedilol AN 3.125, 6.25, 12.5 & 25 mg tablets Carvedilol AN Consumer Medicine Information What is in this leaflet Heart Failure: Carvedilol AN helps to lower your Heart failure occurs when the heart blood pressure. can no longer pump blood strongly This leaflet answers some of the Your doctor may have prescribed enough for the body's needs. Often common questions about Carvedilol Carvedilol AN for another reason. AN. It does not contain all the the heart grows in size to try to available information. It does not improve the blood flow but this can Ask your doctor if you have any take the place of talking to your make the heart failure worse. questions about why Carvedilol AN has been prescribed for you. doctor or pharmacist. Symptoms of heart failure include All medicines have risks and shortness of breath and swelling of benefits. Your doctor has weighed the feet or legs due to fluid build-up. the possible risks of Carvedilol AN Carvedilol AN reduces the pressure Before you take against the expected benefits. that the heart has to pump against as Carvedilol AN If you have any concerns about this well as controlling your heart rate. medicine talk to your doctor or Over 6 months or more this will pharmacist. reduce the size of an oversized heart When you must not take and increase its efficiency. Keep this leaflet until you have Cervedilol AN Carvedilol AN reduces the chances finished treatment with the You must not take Carvedilol AN medicine. of you being admitted to hospital if: You may need to read it again.
    [Show full text]
  • Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: a Literature Review
    medical sciences Review Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: A Literature Review Sachin Relia 1,* and Vijayabharathi Ekambaram 2,* 1 Department of Psychiatry, University of Tennessee Health Sciences Center, 920, Madison Avenue, Suite 200, Memphis, TN 38105, USA 2 Department of Psychiatry, University of Oklahoma Health Sciences Center, 920, Stanton L Young Blvd, Oklahoma City, OK 73104, USA * Correspondence: [email protected] (S.R.); [email protected] (V.E.); Tel.: +1-901-448-4266 (S.R.); +1-405-271-5251 (V.E.); Fax: +1-901-297-6337 (S.R.); +1-405-271-3808 (V.E.) Received: 15 August 2018; Accepted: 17 October 2018; Published: 25 October 2018 Abstract: Autism is a developmental disability that can cause significant emotional, social and behavioral dysfunction. Sleep disorders co-occur in approximately half of the patients with autism spectrum disorder (ASD). Sleep problems in individuals with ASD have also been associated with poor social interaction, increased stereotypy, problems in communication, and overall autistic behavior. Behavioral interventions are considered a primary modality of treatment. There is limited evidence for psychopharmacological treatments in autism; however, these are frequently prescribed. Melatonin, antipsychotics, antidepressants, and α agonists have generally been used with melatonin, having a relatively large body of evidence. Further research and information are needed to guide and individualize treatment for this population group. Keywords: autism spectrum disorder; sleep disorders in ASD; medications for sleep disorders in ASD; comorbidities in ASD 1. Introduction Autism is a developmental disability that can cause significant emotional, social, and behavioral dysfunction. According to the Diagnostic and Statistical Manual (DSM-V) classification [1], autism spectrum disorder (ASD) is characterized by persistent deficits in domains of social communication, social interaction, restricted and repetitive patterns of behavior, interests, or activities.
    [Show full text]
  • Data Sheet SURMONTIL Trimipramine (As Maleate) 25 Mg Tablets and 50 Mg Capsules
    Data Sheet SURMONTIL trimipramine (as maleate) 25 mg tablets and 50 mg capsules Presentation SURMONTIL tablets are compression coated, white or cream, circular, biconvex, containing the equivalent of 25mg trimipramine (as maleate) with a diameter of about 8.0mm. The face is indented with the name and strength, reverse plain. SURMONTIL capsules are opaque white with opaque green cap, printed SU50, each containing the equivalent of 50mg trimipramine (as maleate). Uses Actions SURMONTIL has a potent anti-depressant action similar to that of other tricyclic anti-depressants. The mechanism of action is not fully understood but it is thought to be via inhibition of neuronal re- uptake of noradrenalin, thereby increasing availability. SURMONTIL also possesses a pronounced sedative action. Pharmacokinetics SURMONTIL is readily absorbed after oral administration, reaching a mean peak plasma level after 3 hours. High first pass hepatic clearance results in a mean bioavailability of about 41% of the oral dose, and trimipramine is extensively protein bound in plasma. Elimination half-life is 24 hours. Metabolism is in the liver to its major metabolite, desmethyltrimipramine, which is excreted mainly in the urine. Indications SURMONTIL is indicated in the treatment of depressive illness, especially where sleep disturbance, anxiety or agitation is a presenting symptom. Sleep disturbance is controlled within 24 hours and true anti-depressant action follows within 7-10 days. Dosage and Administration Adults Mild/Moderate Depression in General Practice: The recommended dosage is 50-75 mg orally given two hours before bedtime, the larger dose (75 mg) being preferable for those patients with more marked sleep disturbance.
    [Show full text]
  • Effects of Sympathetic Inhibition on Receptive, Proceptive, and Rejection Behaviors in the Female Rat
    Physiology & Behavior, Vol. 59, No. 3, pp. 537-542, 1996 Copyright © 1996 Elsevier Science Inc. Printed in the USA. All rights reserved 0031-9384/96 $15.00 + .00 ELSEVIER 0031-9384(95)02102-2 Effects of Sympathetic Inhibition on Receptive, Proceptive, and Rejection Behaviors in the Female Rat CINDY M. MESTON, 1 INGRID V. MOE AND BORIS B. GORZALKA Department of Psychology, University of British Columbia, 2136 West Mall, Vancouver, British Columbia, Canada V6T 1Z4 Received 27 September 1994 MESTON, C. M., I. V. MOE AND B. B. GORZALKA. Effects of sympathetic inhibition on receptive, proceptive, and rejection behaviors in the female rat. PHYSIOL BEHAV 59(3) 537-542, 1996.--The present investigation was designed to examine the effects of sympathetic nervous system (SNS) inhibition on sexual behavior in ovariec- tomized, steroid-treated female rats. Clonidine, an alpha2-adrenergic agonist, guanethidine, a postganglionic noradren- ergic blocker, and naphazoline, an alpha2-adrenoreceptor agonist were used to inhibit SNS activity. Intraperitoneal injections of eit:aer 33/zg/ml or 66/xg/ml clonidine significantly decreased receptive (lordosis) and proceptive (ear wiggles) behaviors and significantly increased rejection behaviors (vocalization, kicking, boxing). Either 25 mg/ml or 50 mg/ml guanethidine significantly decreased receptive and proceptive behavior and had no significant effect on rejection behav!iors. Naphazoline significantly inhibited lordosis behavior at either 5 mg/ml or 10 mg/ml doses, significantly inhibited proceptive behavior at 5 mg/ml, and had no significant effect on rejection behaviors. These findings supporc the hypothesis that SNS inhibition decreases sexual activity in the female rat. Lordosis Proceptive behavior Rejection behavior Clonidine Guanethidine Naphazoline Alpha-adrenergic INTRODUCTION as 2 /xg/animal also inhibits lordosis behavior (1).
    [Show full text]